- Testing Types
- In Vitro Bioequivalence (IVBE) Studies Testing
Terms and Conditions
Sample Submission Form
Overview
In vitro bioequivalence (IVBE) evaluates the comparative performance of a proposed test product against its reference product through scientifically designed laboratory studies.
For nasal drug products, performance is influenced by the interaction between the formulation, pump mechanism, nozzle geometry and actuation characteristics. IVBE testing assesses critical performance attributes associated with dose delivery and spray generation, providing quantitative evidence to evaluate product similarity.
Depending on the dosage form and applicable FDA product-specific guidance, these assessments may include single actuation content, droplet size distribution, spray pattern, plume geometry, drug in small particles or droplets, priming and repriming, drug particle size distribution and dissolution.
IVBE studies are structured comparative testing programmes designed around the product’s characteristics, regulatory pathway and specific development objectives.
At PLS Analytical, these programmes bring together controlled mechanical actuation, specialised analytical instrumentation, appropriate sampling strategies and comparative data evaluation. The study design may include predefined testing protocols and endpoints, representative sampling across test and reference batches, method development or qualification, and statistical analysis in line with applicable guidance.
From analytical method optimization and study execution to data evaluation and reporting, the objective is to generate reproducible, traceable and scientifically defensible performance data.
IVBE studies help pharmaceutical developers understand how formulation properties, pump mechanics and spray generation work together to influence nasal drug product performance. By identifying meaningful variations between test and reference products, they provide insights that can guide formulation and device optimisation while helping detect potential performance gaps before pivotal comparative studies or key regulatory milestones.
The resulting comparative data can support product-specific development strategies, including ANDA development and applicable alternative bioequivalence pathways. This helps development teams make more informed decisions and build the analytical evidence required for their regulatory strategy.
Testing Services
Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum
Single Actuation Content (SAC)
Single Actuation Content (SAC)
Quantitative determination of drug content delivered per actuation at defined stages of container life, supporting the assessment of dose delivery consistency between test and reference products.
Droplet Size Distribution (DSD)
Droplet Size Distribution (DSD)
Laser diffraction analysis of spray droplet size profiles, including Dv10, Dv50, Dv90 and span, using Malvern Spraytec technology.
Spray Pattern (SP)
Spray Pattern (SP)
Comparative evaluation of spray footprint characteristics, including major axis, minor axis, area and ovality, using suitable imaging and analytical technology.
Plume Geometry (PG)
Plume Geometry (PG)
Characterisation of spray plume angle, dimensions and development under controlled actuation conditions to evaluate consistency between test and reference products.
Drug in Small Particles or Droplets (DISP)
Drug in Small Particles or Droplets (DISP)
Assessment of drug mass associated with smaller aerodynamic particle or droplet fractions using MSP Next Generation Impactor (NGI) or Andersen Cascade Impactor (ACI) systems.
Priming and Repriming
Priming and Repriming
Comparative evaluation of drug delivery during initial device preparation and following specified periods of non-use.
Drug Particle Size Distribution
Drug Particle Size Distribution
For applicable suspension formulations, assessment of drug-specific particle size and morphology using scientifically suitable analytical techniques.
Dissolution and Additional Physicochemical Characterisation
Dissolution and Additional Physicochemical Characterisation
Where required by product-specific guidance, evaluation of drug dissolution and other formulation attributes that contribute to a comprehensive bioequivalence assessment.
Advantages
Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum Lorum Ipsum
More Informed Formulation and Device Optimisation
Understand the relationship between formulation properties and device mechanics to guide product development.
Greater Insight into Product Variability
Evaluate differences across individual units and manufacturing batches to build a clearer picture of product performance.
Early Identification of Performance Gaps
Identify potential differences in dose delivery, spray characteristics and other critical attributes before key development milestones.
